Mourad Sanhaji

10PUBLICATIONS
10CO-AUTHORS
Molecular targetsReaction engineering (excl. nuclear reactions)Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 28, 2026
Correction: Raab et al. Truncated DAPK Variants Restore Tumor Suppressor Activity and Synergize with Standard Therapies in High-Grade Serous Ovarian Cancer. Cancers 2025, 17, 1910.

|Jun 26, 2025
Truncated DAPK Variants Restore Tumor Suppressor Activity and Synergize with Standard Therapies in High-Grade Serous Ovarian Cancer.

Monika Raab, Khayal Gasimli, Balázs Győrffy

|May 20, 2025
Targeted reactivation of the novel tumor suppressor DAPK1, an upstream regulator of p53, in high-grade serous ovarian cancer by mRNA liposomes reduces viability and enhances drug sensitivity in preclinical models.

Monika Raab, Balázs Győrffy, Samuel Peña-Llopis

|Jan 11, 2024
Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors.

Khayal Gasimli, Monika Raab, Ranadip Mandal

|Jul 24, 2023
Correction: A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1.

Monika Raab, Yves Matthess, Christopher A Raab

|Feb 22, 2023
Correction: The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer.

Ranadip Mandal, Monika Raab, Franz Rödel

Pageof 2

Frequent Collaborators

8 joint publications

Klaus Strebhardt

5 joint publications

Samuel Peña-Llopis

4 joint publications

Khayal Gasimli

4 joint publications

Ranadip Mandal